我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
10
2 进行中
药物批准
11
批准总数
监管机构
3
监管机构数
成立时间
N/A
进行中（未招募）
2
20.0%
已完成
6
60.0%
招募中
EMA
European Medicines Agency
EMC
Electronic Medicines Compendium
1
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
4
- Norgine has entered a definitive agreement to acquire Theravia from Mérieux Equity Partners, adding key rare disease treatments SIKLOS® for sickle cell disease and ORPHACOL® for genetic bile disorders to its portfolio. - The acquisition aligns with Norgine's growth strategy, creating a European-based rare disease champion with six core products that will serve as key growth drivers in the medium-to-long term. - This transaction follows Norgine's recent deals with Fennec Pharma for PEDMARQSI® and X4 Pharma for mavorixafor, establishing the company as a partner of choice for commercializing rare and specialty pharmaceuticals in Europe.
